Literature DB >> 24593938

Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes.

Reshef Tal1, David B Seifer2, Moisey Khanimov2, Henry E Malter2, Richard V Grazi2, Ben Leader3.   

Abstract

OBJECTIVE: Serum Antimüllerian hormone (AMH) levels are elevated in polycystic ovarian syndrome and have been shown to be useful in its diagnosis. However, the clinical significance of extremely high AMH levels is understudied. We aimed to characterize a population of women with elevated AMH (>5 ng/mL). STUDY
DESIGN: This was a retrospective cohort study of 134 women presenting to our fertility clinic for infertility evaluation and treatment who were found to have random serum AMH over 5 ng/mL. Women were divided into 3 groups according to AMH: 5-10 ng/mL, >10-14 ng/mL, and >14 ng/mL. Endocrine characteristics, polycystic ovarian syndrome (PCOS) phenotypes, fertilization rate, implantation rate, clinical pregnancy, and multiple pregnancy rates were compared between groups.
RESULTS: AMH ranged between 5 to 48 ng/mL. Greater than 97% of women with ultrahigh AMH (>10 ng/mL) had PCOS. In addition, women with AMH >10 ng/mL had greater prevalence of polycystic ovarian morphology and oligoamenorrhea than women with AMH 5-10 ng/mL. Moreover, serum AMH correlated positively with luteinizing hormone, total testosterone, and dehydroepiandrosterone sulfate. Furthermore, AMH showed strong predictive ability for the presence of amenorrhea (area under the curve, 0.87; 95% confidence interval, 0.80-0.92; P < .0001). Despite similar age and mean number of transferred embryos, women with AMH >10 ng/mL showed higher rates of ovarian hyperstimulation syndrome and clinical pregnancy rates compared with women with AMH 5-10 ng/mL.
CONCLUSION: These data characterize a population of women with elevated AMH levels, demonstrating that the vast majority of women with AMH >10 ng/mL have PCOS. Increased AMH levels correlated with PCOS severity and are associated with greater ovarian stimulation and higher clinical pregnancy rates following assisted reproductive technology.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  antimüllerian hormone (AMH); assisted reproductive technology (ART); outcomes; polycystic ovarian syndrome (PCOS); ultrahigh AMH

Mesh:

Substances:

Year:  2014        PMID: 24593938     DOI: 10.1016/j.ajog.2014.02.026

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  29 in total

1.  Anti-Müllerian hormone is all you need: an assisted reproductive technology perspective in diagnosing polycystic ovary syndrome.

Authors:  Kate McCullough; William Ledger
Journal:  Womens Health (Lond)       Date:  2016-05-11

2.  Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys.

Authors:  D H Abbott; B H Rayome; D A Dumesic; K C Lewis; A K Edwards; K Wallen; M E Wilson; S E Appt; J E Levine
Journal:  Hum Reprod       Date:  2017-04-01       Impact factor: 6.918

Review 3.  Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.

Authors:  Vitaly A Kushnir; David B Seifer; David H Barad; Aritro Sen; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2017-06-22       Impact factor: 3.412

4.  Antimullerian Hormone Levels and Association with Abortion and Preterm Delivery in Patients with Polycystic Ovary Syndrome Who Conceived with Assisted Reproductive Techniques.

Authors:  Walid A Abdelsalam; Ola A Harb; Sherin A Shazly
Journal:  J Obstet Gynaecol India       Date:  2022-01-04

5.  Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome.

Authors:  Sunni L Mumford; Richard S Legro; Michael P Diamond; Christos Coutifaris; Anne Z Steiner; William D Schlaff; Ruben Alvero; Gregory M Christman; Peter R Casson; Hao Huang; Nanette Santoro; Esther Eisenberg; Heping Zhang; Marcelle I Cedars
Journal:  J Clin Endocrinol Metab       Date:  2016-05-26       Impact factor: 5.958

6.  Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome.

Authors:  Upma Saxena; Manisha Ramani; Pushpa Singh
Journal:  J Obstet Gynaecol India       Date:  2017-11-15

7.  High Serum Anti-Müllerian Hormone Concentrations Are Associated With Poor Pregnancy Outcome in Fresh IVF/ICSI Cycle but Not Cumulative Live Birth Rate in PCOS Patients.

Authors:  Yaxin Guo; Shuai Liu; Shiqiao Hu; Fei Li; Lei Jin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-26       Impact factor: 5.555

8.  Response to ovulation induction treatments in women with polycystic ovary syndrome as a function of serum anti-Müllerian hormone levels.

Authors:  Stylianos Vagios; Caitlin R Sacha; Karissa C Hammer; Irene Dimitriadis; Kaitlyn E James; Charles L Bormann; Irene Souter
Journal:  J Assist Reprod Genet       Date:  2021-05-01       Impact factor: 3.357

Review 9.  Maximizing the clinical utility of antimüllerian hormone testing in women's health.

Authors:  Benjamin Leader; Valerie L Baker
Journal:  Curr Opin Obstet Gynecol       Date:  2014-08       Impact factor: 1.927

10.  Does vitamin D supplementation improve ovarian reserve in women with diminished ovarian reserve and vitamin D deficiency: a before-and-after intervention study.

Authors:  Shahintaj Aramesh; Touran Alifarja; Ramin Jannesar; Parvin Ghaffari; Raziyeh Vanda; Fatemeh Bazarganipour
Journal:  BMC Endocr Disord       Date:  2021-06-21       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.